Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Stock Has Average Price Target of $23.36

Shares of Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) have been given an average rating of “Moderate Buy” by the seventeen brokerages that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $23.36.

Several equities research analysts recently issued reports on CMPS shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Compass Pathways in a research note on Friday, July 17th. Morgan Stanley raised their target price on Compass Pathways from $17.00 to $18.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. HC Wainwright reduced their price target on Compass Pathways from $70.00 to $65.00 and set a “buy” rating for the company in a research report on Friday, August 7th. Jefferies Financial Group reiterated a “buy” rating on shares of Compass Pathways in a research note on Wednesday, September 9th. Finally, Compass Point set a $25.00 price objective on Compass Pathways in a report on Tuesday, July 7th.

Compass Pathways Price Performance

Shares of CMPS opened at $11.69 on Thursday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.30 and a current ratio of 1.30. The firm has a market cap of $1.62 billion, a PE ratio of -2.53 and a beta of 2.55. The firm’s 50 day moving average price is $13.44 and its 200 day moving average price is $11.41. Compass Pathways has a twelve month low of $4.88 and a twelve month high of $15.87.

Compass Pathways (NASDAQ:CMPS) last posted its earnings results on Wednesday, August 5th. The company reported ($1.88) EPS for the quarter, missing the consensus estimate of ($0.39) by ($1.49). As a group, research analysts expect that Compass Pathways will post -1.26 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. QRG Capital Management Inc. bought a new stake in Compass Pathways during the second quarter valued at about $688,000. WINTON GROUP Ltd grew its position in Compass Pathways by 20.1% in the 2nd quarter. WINTON GROUP Ltd now owns 17,900 shares of the company’s stock worth $253,000 after purchasing an additional 3,000 shares during the last quarter. Integrated Wealth Concepts LLC acquired a new position in shares of Compass Pathways during the second quarter valued at about $351,000. Squarepoint Ops LLC raised its position in shares of Compass Pathways by 751.1% during the second quarter. Squarepoint Ops LLC now owns 138,671 shares of the company’s stock valued at $1,962,000 after buying an additional 122,378 shares during the last quarter. Finally, TD Waterhouse Canada Inc. lifted its stake in shares of Compass Pathways by 4,292.2% in the second quarter. TD Waterhouse Canada Inc. now owns 30,306 shares of the company’s stock valued at $402,000 after buying an additional 29,616 shares during the period. Institutional investors and hedge funds own 46.19% of the company’s stock.

About Compass Pathways

Compass Pathways plc is a biotechnology company developing psychedelic treatments for mental health conditions. The company’s lead investigational product is COMP360, a proprietary formulation of synthetic psilocybin administered with psychological support in a controlled clinical setting.

Compass Pathways has focused primarily on treatment-resistant depression, a condition in which patients do not achieve adequate relief from standard therapies. Its research has also explored the potential use of COMP360 in other serious mental health disorders.